ID   M238 R2
AC   CVCL_EI92
SY   M238-AR2; M238AR
DR   cancercelllines; CVCL_EI92
DR   Cosmic; 1545617
DR   Wikidata; Q54903553
RX   PubMed=21107323;
RX   PubMed=22194965;
RX   PubMed=24735930;
CC   Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Heterozygous (PubMed=22194965).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D751 ! M238
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 19-12-24; Version: 12
//
RX   PubMed=21107323; DOI=10.1038/nature09626; PMCID=PMC3143360;
RA   Nazarian R., Shi H.-B., Wang Q., Kong X.-J., Koya R.C., Lee H.,
RA   Chen Z.-G., Lee M.-K., Attar N., Sazegar H., Chodon T., Nelson S.F.,
RA   McArthur G.A., Sosman J.A., Ribas A., Lo R.S.;
RT   "Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or
RT   N-RAS upregulation.";
RL   Nature 468:973-977(2010).
//
RX   PubMed=22194965; DOI=10.1371/journal.pone.0028973; PMCID=PMC3237573;
RA   Atefi M., von Euw E.M., Attar N., Ng C., Chu C., Guo D.-L., Nazarian R.,
RA   Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S.,
RA   Ribas A.;
RT   "Reversing melanoma cross-resistance to BRAF and MEK inhibitors by
RT   co-targeting the AKT/mTOR pathway.";
RL   PLoS ONE 6:E28973-E28973(2011).
//
RX   PubMed=24735930; DOI=10.1186/1476-4598-13-83; PMCID=PMC4021505;
RA   Lassen A., Atefi M., Robert L., Wong D.J.L., Cerniglia M.,
RA   Comin-Anduix B., Ribas A.;
RT   "Effects of AKT inhibitor therapy in response and resistance to BRAF
RT   inhibition in melanoma.";
RL   Mol. Cancer 13:83.1-83.14(2014).
//